Post A Reply
my profile
login
|
register
|
search
|
faq
|
forum home
»
Allstocks.com's Bulletin Board
»
.11 and Up!
»
ACTC--NEWS
» Post A Reply
Post A Reply
Login Name:
Password:
Message Icon:
Message:
HTML is enabled.
UBB Code™ is enabled.
[QUOTE]Originally posted by IMAKEMONEY: [QB] Advanced Cell Technology Applauds Inclusion of Stem Cell Provision In $152 Billion Federal Funding Measure Jul 2, 2007 09:51:07 (ET) ALAMEDA, Calif., Jul 02, 2007 (BUSINESS WIRE) -- Advanced Cell Technology, Inc.(ACTC, Trade ): On June 21, 2007, the U.S. Senate Appropriations Committee voted overwhelmingly in favor of a $152 billion Labor-HHS-Education appropriations bill. An amendment to the bill would expand federal funding for embryonic stem cell research by changing a critical date relating to the eligibility of stem cell lines. The amendment would fundamentally change current federal embryonic stem cell policy by permitting federally-funded research on stem cell lines that were derived before June 15 of this year, as opposed to the current marker of August 9, 2001. The committee noted that this moving of the date forward by almost six years will advance progress toward treatments and cures by significantly expanding the number of stem cell lines eligible for federally funded research. Key among those lines would be upwards of twenty from Advanced Cell Technology (ACTC). These would include the Company's single cell blastomere lines, created without the destruction of embryos. This technique was documented in a major paper in Nature magazine in August 2006. Moreover, the Company recently announced additional lines using this embryo-safe technique, as discussed by ACTC's Chairman and CEO, William M. Caldwell, IV, in an interview on Bloomberg TV on June 20, juxtaposed with President Bush's press conference on related topics. The legislation would provide more than $29 billion to fund biomedical research at the 27 Institutes and Centers that comprise the National Institutes of Health (NIH). This represents an increase of $1 billion over the fiscal year 2007 level and more than $1.2 billion over the President's most recent budget request. Subcommittee Chairman Tom Harkin (D-IA) said, "We have written a bill that, I believe, reflects the real priorities and values of the American people. The bill provides $29 billion for life-saving biomedical research at the National Institutes of Health." In this same regard, Senate Appropriation Committee Chairman Robert C. Byrd (D-WV) noted, "The future of our nation and its ability to dominate in the global economy depends on the strength of our workforce, our ability to give our children access to an education that is second to none, and invest in our research facilities so that our doctors and scientists can continue to find cures for illnesses that affect millions of Americans every year." William M. Caldwell IV urged the NIH to look favorably on all current grant applications utilizing the Company's single cell blastomere technology, saying, "If the NIH approves funding for human embryonic stem cell lines derived from a well-established, widely-used medical procedure, pre-implantation genetic diagnosis (PGD), the United States scientific and biotechnology community will have the opportunity to accelerate this technology platform which does not destroy the embryo, and translate the existing body of science into therapies destined for clinical trials. Over 2,500 children have been born in the past few years through PGD. They are alive and healthy, with loving parents and are a walking testament to the viability of PGD, which is the basis for our single cell blastomere technology." Mr. Caldwell added, "Unlike a recently-announced technique for deriving embryonic stems cells in mice, this is not a science project years away from being utilized for therapeutic work. These embryonic stem cell lines we have developed are available today, here and now, and may be used immediately." To read more on the spending measure, please visit http://appropriations.senate.gov/ To watch Mr. Caldwell's June 20 interview on federal stem cell funding on Bloomberg Television, please visit ACTC's website at http://www.advancedcell.com About Advanced Cell Technology, Inc. Advanced Cell Technology, Inc. is a biotechnology company applying embryonic stem cell technology in the emerging field of regenerative medicine. The company operates facilities in Alameda, California and Worcester, Massachusetts. For more information, please visit: [URL=http://www.advancedcell.com]www.advancedcell.com[/URL] . Forward-Looking Statements Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports, including the report on Form 10-QSB for the quarter ending March 31, 2007. Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change. SOURCE: Advanced Cell Technology, Inc. The Investor Relations Group Media: Bill Douglass, 212-825-3210 or Investors: Joseph Kessler/James Carbonara, 212-825-3210 [/QB][/QUOTE]
Instant Graemlins
Instant UBB Code™
What is UBB Code™?
Options
Disable Graemlins in this post.
*** Click here to review this topic. ***
Contact Us
|
Allstocks.com Message Board Home
© 1997 - 2021 Allstocks.com. All rights reserved.
Powered by
Infopop Corporation
UBB.classic™ 6.7.2